FDA clears first swept-source OCT platform for posterior imaging

The PLEX Elite 9000, a Swept-Source OCT and OCT Angiography platform, was designed for advanced retina research and is at the core of the Advanced Retina Imaging (ARI) Network, a global consortium of clinicians and scientists focusing on exploring new clinical applications for the diagnosis and treatment of eye disease and advancing OCT innovation.

“Zeiss’ swept-source OCT and OCT angiography platform is truly a remarkable breakthrough in our quest to achieve better, wider, deeper, and faster imaging of the retina and choroid. This instrument opens up a new world of structural and microvascular clarity. By imaging deeper and in greater detail than ever before, we will further our understanding of the retina and choroid, and greatly facilitate clinical trial investigations into different diseases,” said Philip J. Rosenfeld, MD, PhD, chairman of the ARI Network. “This collaboration between the retina experts in the ARI Network and the engineers and scientists at Zeiss is vital to the advancement of retinal and choroidal imaging and scientific discovery.”

The platform will be limited as research tool for clinicians conducting retina research. According to the press release, the approval could facilitate easier patient enrollment and faster Institutional Review Board reviews for research approval.